If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...
The FDA has extended the review period of the New Drug Application for tolebrutinib for the treatment of non-relapsing, secondary progressive MS and to slow disability accumulation independent of ...
It could soon get easier for Georgians with health insurance through the state’s Pathways to Coverage Medicaid program to maintain coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback